Cargando…

Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma

We report the activity and toxicity of docetaxel in 12 evaluable heavily pretreated patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. In all, 42% achieved a partial response, 25% achieved stable disease. Median duration of response was 16 (10–21) weeks. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zekri, J M, Hough, R E, Davies, J M, Molife, R, Hancock, B W, Lorigan, P C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741047/ https://www.ncbi.nlm.nih.gov/pubmed/12778057 http://dx.doi.org/10.1038/sj.bjc.6600914

Ejemplares similares

Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer
por: Lordick, F, et al.
Publicado: (2003)

A Phase II Study of Docetaxel in Patients with Relapsed and Refractory Ewing's Tumours
por: Meyer, T., et al.
Publicado: (2003)

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
por: Dawson, Mark A., et al.
Publicado: (2023)

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
por: Younes, A, et al.
Publicado: (2010)

Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer
por: Galli, L, et al.
Publicado: (2007)

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer
por: del Muro, X García, et al.
Publicado: (2002)

A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers
por: Wu, C, et al.
Publicado: (2015)

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
por: Blagden, S P, et al.
Publicado: (2008)

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2006)

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
por: Major, Ajay, et al.
Publicado: (2021)

A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial
por: Fox, Christopher P., et al.
Publicado: (2021)

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study
por: Carles, J, et al.
Publicado: (2007)

A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma
por: Cavenagh, J, et al.
Publicado: (2017)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib
por: Arakawa, Yoshiki, et al.
Publicado: (2023)

Second primary malignancies after treatment for malignant lymphoma
por: Okines, A, et al.
Publicado: (2005)

Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study
por: Kim, Won-Seog, et al.
Publicado: (2023)

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma
por: Ng, M, et al.
Publicado: (2005)

Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
por: Narita, Yoshitaka, et al.
Publicado: (2020)

Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study
por: Nicolay, Jan P., et al.
Publicado: (2023)

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
por: Shimony, Shai, et al.
Publicado: (2022)

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
por: Tebbutt, N C, et al.
Publicado: (2013)

Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group
por: Buckstein, Rena, et al.
Publicado: (2011)

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2008)

Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
por: Ma, Xinran, et al.
Publicado: (2020)

Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
por: Bousquet, G, et al.
Publicado: (2011)

Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma – a phase II study
por: Morschhauser, Franck, et al.
Publicado: (2020)

Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma
por: Hough, R E, et al.
Publicado: (2001)

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer
por: Park, Y H, et al.
Publicado: (2004)

Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma
por: Qian, Zhengzi, et al.
Publicado: (2015)

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
por: Kollmannsberger, C, et al.
Publicado: (2002)

Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study
por: Urup, T, et al.
Publicado: (2013)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
por: Dreyling, M., et al.
Publicado: (2017)

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
por: Ciardiello, F, et al.
Publicado: (2006)

Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma
por: Evens, Andrew M., et al.
Publicado: (2022)

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
por: Liu, Yang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_38bnrpj9ca45dogdvkv5tc0g4d